The CONQUEST study is researching 2 investigational medicines, each a potential systemic sclerosis associated interstitial lung disease (SSc-ILD) therapy.
If you are eligible and decide to join, you will be assigned at random to 1 of 2 investigational medicines or a placebo. Placebos look like the investigational medicine, but they do not have therapeutic effects. Study staff will give you more information about the investigational medicines and dosing instructions.
Investigational means the study medication is not yet approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like the CONQUEST SSc-ILD clinical trial.